Irofulven as first line therapy in recurrent or metastatic gastric cancer: A phase II multicenter study by the Cancer Therapeutics Research Group (CTRG)

W. Yeo, M. Boyer, H. C. Chung, S. Y.K. Ong, R. Lim, Benny Zee, B. Ma, K. C. Lam, F. K.F. Mo, E. K.W. Ng, R. Ho, S. Clarke, J. K. Roh, P. Beale, S. Y. Rha, H. C. Jeung, R. Soo, B. C. Goh, A. T.C. Chan

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: The purpose of this study was to evaluate the tolerability and efficacy of irofulven, a DNA interacting acylfulvene analog, as first line therapy for patients with recurrent or metastatic gastric cancer. Patients and methods: Twenty-three patients with recurrent or metastatic gastric cancer received irofulven at a dose of 0.45 mg/kg administered intravenously over 30-min infusion (up to a maximum of 50 mg), on days 1 and 8, every 3 weeks. Results: The median number of cycles delivered per patient was 2 (range 1-6). Two patients (9%) had ≥1-week delay in administration of subsequent cycle of chemotherapy. For the day 8 chemotherapy, dose reductions were required in seven patients (30%); dose omitting occurred in five patients (22%). Grade 3/4 anemia and neutropenia occurred in 22 and 17% of patients, respectively. There was no grade 4 thrombocytopenia and no neutropenic fever was observed. Of the 20 evaluable patients, there were no responses observed, 3 patients had stable disease after 2 cycles of treatment which was not confirmed by a further assessment. Median overall survival was 6.05 months (95% CI 4.55-9.39). Conclusions: Irofulven was tolerated at the dose of 0.45 mg/kg on days 1 and 8, every 3 weeks but showed no evidence of antitumor activity in patients with advanced gastric cancer.

Original languageEnglish
Pages (from-to)295-300
Number of pages6
JournalCancer Chemotherapy and Pharmacology
Volume59
Issue number3
DOIs
Publication statusPublished - 2007 Mar 1

Fingerprint

Therapeutic Human Experimentation
Multicenter Studies
Stomach Neoplasms
Chemotherapy
Neoplasms
Therapeutics
DNA
irofulven
Drug Therapy
Neutropenia
Anemia
Fever

All Science Journal Classification (ASJC) codes

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Yeo, W. ; Boyer, M. ; Chung, H. C. ; Ong, S. Y.K. ; Lim, R. ; Zee, Benny ; Ma, B. ; Lam, K. C. ; Mo, F. K.F. ; Ng, E. K.W. ; Ho, R. ; Clarke, S. ; Roh, J. K. ; Beale, P. ; Rha, S. Y. ; Jeung, H. C. ; Soo, R. ; Goh, B. C. ; Chan, A. T.C. / Irofulven as first line therapy in recurrent or metastatic gastric cancer : A phase II multicenter study by the Cancer Therapeutics Research Group (CTRG). In: Cancer Chemotherapy and Pharmacology. 2007 ; Vol. 59, No. 3. pp. 295-300.
@article{9ed69c0561394c3e8e16ce48dff6a104,
title = "Irofulven as first line therapy in recurrent or metastatic gastric cancer: A phase II multicenter study by the Cancer Therapeutics Research Group (CTRG)",
abstract = "Background: The purpose of this study was to evaluate the tolerability and efficacy of irofulven, a DNA interacting acylfulvene analog, as first line therapy for patients with recurrent or metastatic gastric cancer. Patients and methods: Twenty-three patients with recurrent or metastatic gastric cancer received irofulven at a dose of 0.45 mg/kg administered intravenously over 30-min infusion (up to a maximum of 50 mg), on days 1 and 8, every 3 weeks. Results: The median number of cycles delivered per patient was 2 (range 1-6). Two patients (9{\%}) had ≥1-week delay in administration of subsequent cycle of chemotherapy. For the day 8 chemotherapy, dose reductions were required in seven patients (30{\%}); dose omitting occurred in five patients (22{\%}). Grade 3/4 anemia and neutropenia occurred in 22 and 17{\%} of patients, respectively. There was no grade 4 thrombocytopenia and no neutropenic fever was observed. Of the 20 evaluable patients, there were no responses observed, 3 patients had stable disease after 2 cycles of treatment which was not confirmed by a further assessment. Median overall survival was 6.05 months (95{\%} CI 4.55-9.39). Conclusions: Irofulven was tolerated at the dose of 0.45 mg/kg on days 1 and 8, every 3 weeks but showed no evidence of antitumor activity in patients with advanced gastric cancer.",
author = "W. Yeo and M. Boyer and Chung, {H. C.} and Ong, {S. Y.K.} and R. Lim and Benny Zee and B. Ma and Lam, {K. C.} and Mo, {F. K.F.} and Ng, {E. K.W.} and R. Ho and S. Clarke and Roh, {J. K.} and P. Beale and Rha, {S. Y.} and Jeung, {H. C.} and R. Soo and Goh, {B. C.} and Chan, {A. T.C.}",
year = "2007",
month = "3",
day = "1",
doi = "10.1007/s00280-006-0270-1",
language = "English",
volume = "59",
pages = "295--300",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "3",

}

Yeo, W, Boyer, M, Chung, HC, Ong, SYK, Lim, R, Zee, B, Ma, B, Lam, KC, Mo, FKF, Ng, EKW, Ho, R, Clarke, S, Roh, JK, Beale, P, Rha, SY, Jeung, HC, Soo, R, Goh, BC & Chan, ATC 2007, 'Irofulven as first line therapy in recurrent or metastatic gastric cancer: A phase II multicenter study by the Cancer Therapeutics Research Group (CTRG)', Cancer Chemotherapy and Pharmacology, vol. 59, no. 3, pp. 295-300. https://doi.org/10.1007/s00280-006-0270-1

Irofulven as first line therapy in recurrent or metastatic gastric cancer : A phase II multicenter study by the Cancer Therapeutics Research Group (CTRG). / Yeo, W.; Boyer, M.; Chung, H. C.; Ong, S. Y.K.; Lim, R.; Zee, Benny; Ma, B.; Lam, K. C.; Mo, F. K.F.; Ng, E. K.W.; Ho, R.; Clarke, S.; Roh, J. K.; Beale, P.; Rha, S. Y.; Jeung, H. C.; Soo, R.; Goh, B. C.; Chan, A. T.C.

In: Cancer Chemotherapy and Pharmacology, Vol. 59, No. 3, 01.03.2007, p. 295-300.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Irofulven as first line therapy in recurrent or metastatic gastric cancer

T2 - A phase II multicenter study by the Cancer Therapeutics Research Group (CTRG)

AU - Yeo, W.

AU - Boyer, M.

AU - Chung, H. C.

AU - Ong, S. Y.K.

AU - Lim, R.

AU - Zee, Benny

AU - Ma, B.

AU - Lam, K. C.

AU - Mo, F. K.F.

AU - Ng, E. K.W.

AU - Ho, R.

AU - Clarke, S.

AU - Roh, J. K.

AU - Beale, P.

AU - Rha, S. Y.

AU - Jeung, H. C.

AU - Soo, R.

AU - Goh, B. C.

AU - Chan, A. T.C.

PY - 2007/3/1

Y1 - 2007/3/1

N2 - Background: The purpose of this study was to evaluate the tolerability and efficacy of irofulven, a DNA interacting acylfulvene analog, as first line therapy for patients with recurrent or metastatic gastric cancer. Patients and methods: Twenty-three patients with recurrent or metastatic gastric cancer received irofulven at a dose of 0.45 mg/kg administered intravenously over 30-min infusion (up to a maximum of 50 mg), on days 1 and 8, every 3 weeks. Results: The median number of cycles delivered per patient was 2 (range 1-6). Two patients (9%) had ≥1-week delay in administration of subsequent cycle of chemotherapy. For the day 8 chemotherapy, dose reductions were required in seven patients (30%); dose omitting occurred in five patients (22%). Grade 3/4 anemia and neutropenia occurred in 22 and 17% of patients, respectively. There was no grade 4 thrombocytopenia and no neutropenic fever was observed. Of the 20 evaluable patients, there were no responses observed, 3 patients had stable disease after 2 cycles of treatment which was not confirmed by a further assessment. Median overall survival was 6.05 months (95% CI 4.55-9.39). Conclusions: Irofulven was tolerated at the dose of 0.45 mg/kg on days 1 and 8, every 3 weeks but showed no evidence of antitumor activity in patients with advanced gastric cancer.

AB - Background: The purpose of this study was to evaluate the tolerability and efficacy of irofulven, a DNA interacting acylfulvene analog, as first line therapy for patients with recurrent or metastatic gastric cancer. Patients and methods: Twenty-three patients with recurrent or metastatic gastric cancer received irofulven at a dose of 0.45 mg/kg administered intravenously over 30-min infusion (up to a maximum of 50 mg), on days 1 and 8, every 3 weeks. Results: The median number of cycles delivered per patient was 2 (range 1-6). Two patients (9%) had ≥1-week delay in administration of subsequent cycle of chemotherapy. For the day 8 chemotherapy, dose reductions were required in seven patients (30%); dose omitting occurred in five patients (22%). Grade 3/4 anemia and neutropenia occurred in 22 and 17% of patients, respectively. There was no grade 4 thrombocytopenia and no neutropenic fever was observed. Of the 20 evaluable patients, there were no responses observed, 3 patients had stable disease after 2 cycles of treatment which was not confirmed by a further assessment. Median overall survival was 6.05 months (95% CI 4.55-9.39). Conclusions: Irofulven was tolerated at the dose of 0.45 mg/kg on days 1 and 8, every 3 weeks but showed no evidence of antitumor activity in patients with advanced gastric cancer.

UR - http://www.scopus.com/inward/record.url?scp=33845873055&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845873055&partnerID=8YFLogxK

U2 - 10.1007/s00280-006-0270-1

DO - 10.1007/s00280-006-0270-1

M3 - Article

C2 - 16783579

AN - SCOPUS:33845873055

VL - 59

SP - 295

EP - 300

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 3

ER -